Two medications used in physician-supervised weight management are semaglutide and tirzepatide. Brand-name products commonly discussed in this context include Ozempic, Wegovy, Mounjaro, and Zepbound. Semaglutide and tirzepatide work differently, and the differences matter.
How They Work
Semaglutide — GLP-1 receptor agonist
Semaglutide mimics glucagon-like peptide 1 (GLP-1), a hormone naturally released after eating. It slows gastric emptying, reduces appetite signals in the brain, and helps regulate blood sugar. The result: you feel full faster, stay full longer, and eat less without fighting constant hunger.
Tirzepatide — Dual GIP/GLP-1 receptor agonist
Tirzepatide does everything semaglutide does — plus it activates a second hormone pathway: glucose-dependent insulinotropic polypeptide (GIP). GIP plays a role in fat storage and insulin sensitivity. By targeting both receptors, tirzepatide may produce stronger appetite suppression and metabolic effects in some patients.
How Do the Results Compare?
In clinical trials of the FDA-approved brand-name products (Wegovy, Zepbound), semaglutide showed an average body weight reduction of about 15–17% and tirzepatide about 20–22%. Compounded medications are not FDA-approved and were not studied in these trials; individual results vary. Some people respond better to one medication than the other; your physician will explain which option may fit you.
Side Effects: What to Expect
Both medications share overlapping side effects, most of which are gastrointestinal and tend to be strongest early on:
- Nausea (very common, especially in the first 4–8 weeks)
- Vomiting or diarrhea
- Constipation
- Decreased appetite (this is partly the mechanism, not just a side effect)
- Fatigue
Both carry rare but serious risks that your physician will review with you — including pancreatitis and, in rodent studies, thyroid C-cell tumors (though this has not been established in humans). They are contraindicated in patients with a personal or family history of medullary thyroid cancer or MEN2.
Which One Is Right for You?
This is genuinely a question for your physician — not something to decide based on an article. Factors your provider will weigh include:
- Your starting weight and weight-loss goals
- History of diabetes or prediabetes (tirzepatide has an edge on blood sugar control)
- Tolerance to GI side effects
- Cost and what's available through your program
- Prior medication history
Southern Vitality offers both compounded semaglutide and tirzepatide protocols. Your intake is reviewed by a licensed physician who recommends the most appropriate starting point for your specific situation.
Cost Difference
Southern Vitality compounded semaglutide starts at a $79/month equivalent ($948 paid upfront for 12 months), and compounded tirzepatide starts at a $120/month equivalent ($1,440 paid upfront for 12 months). These are monthly equivalents, not monthly billing; each 12-month amount is paid upfront and does not automatically renew. A physician must evaluate you before prescribing. Separately, brand-name tirzepatide (Zepbound) retail pricing is often listed at $1,000–$1,500/month; this is brand-name retail pricing, not a Southern Vitality program price.